Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


DANVERS, Mass., March 27, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq: ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E. Washington Convention Center in Washington, DC.

On the ACC show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #1407 and hands-on simulations of the Impella platform.

For further information about the ACC scientific sessions and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

CONTACT: Aimee Genzler Corporate Communications Manager 978-646-1553 ir@abiomed.com


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Press Releases